In contrast to other malignancies, many patients diagnosed with breast cancer gain weight after diagnosis. A recent review of the literature from 1997 to 2009 showed that 34%--100% of patients gained weight post-diagnosis, and mean weight gain ranged from 0.27 to 7.3 kg over follow-up period ranging from 6 months to 5 years ([@bib72]), values that are higher than in the general population ([@bib76]; [@bib75]). This is especially significant in the breast cancer population as obesity at diagnosis ([@bib7]; [@bib46]; [@bib54]; [@bib52]; [@bib72]) and weight gain after diagnosis ([@bib4]; [@bib7]; [@bib46]) have both been shown to be associated with poor prognosis, including increased cancer recurrence, decreased overall and breast cancer-associated survival, and decreased response to chemotherapy in addition to decreased quality of life.

Studies have shown an association of clinical variables with this weight gain, including baseline age and body mass index (BMI), treatment factors such as chemotherapy and hormone therapy, tumour characteristics such as stage, and menopausal status, but with conflicting findings ([@bib4]; [@bib47]; [@bib13], [@bib14]; [@bib1]; [@bib11]; [@bib22]; [@bib48]; [@bib10]; [@bib51]; [@bib61]; [@bib18]; [@bib37]; [@bib38]; [@bib46]; [@bib3]; [@bib5]; [@bib62]; [@bib25]; [@bib32]; [@bib24]). In the general population, there is an important genetic background that contributes to obesity and weight gain ([@bib17]; [@bib66]). *FTO*, fat mass and obesity-associated protein, was recently found in genome-wide association studies (GWAS) to be associated with obesity and is a protein predominantly expressed in the hypothalamus and cerebellum. It is thought to mediate its effect on weight by decreasing satiety and activity levels ([@bib34]; [@bib60]; [@bib74]). We previously published a case--control study showing that *FTO* is expressed in both normal and malignant breast tissue and that *FTO* polymorphisms are associated with breast cancer risk ([@bib41]). Adiponectin is an endogenous insulin sensitiser that regulates the secretion of insulin-like growth factor, oestrogens, and tumour necrosis factor, and along with its receptors has also been shown to be associated with weight gain as well as diabetes and cardiovascular disease ([@bib58]; [@bib68]; [@bib70]; [@bib77]; [@bib55]; [@bib15]). We have also previously published data linking polymorphisms in the adiponectin gene (*ADIPOQ*) and its receptor (*ADIPOR1*) to breast cancer risk ([@bib43]). To our knowledge, no studies have investigated the effects of genetic variables on weight gain after breast cancer diagnosis.

The purpose of our study is to investigate the contribution to post-diagnosis weight gain of genetic polymorphisms in *FTO, ADIPOQ,* and *ADIPOR1*, clinical variables, and gene × environment interactions in breast cancer patients. By developing and comparing various predictive models, we aim to create a risk prediction tool that can be used clinically to isolate a high-risk patient population for targeted weight loss interventions.

Materials and methods
=====================

Study participants
------------------

Patients were recruited from the medical oncology clinics at Robert H Lurie Comprehensive Cancer Centre from August 2007 to December 2009. All patients signed an informed consent for study participation and for genetic studies, and the protocol was approved by the Institutional Review Board of Northwestern University. Inclusion criteria included diagnosis of stages I--III breast cancer, age ⩾18 years, and female sex. Exclusion criteria included presence of *in situ* only cancer, metastatic disease, pregnancy, or poorly controlled diseases that can independently results in weight changes such as thyroid disease or systemic infection.

Chart review
------------

A retrospective chart review was conducted on recruited patients to obtain weights and BMIs over an 18-month period from diagnosis, tumour characteristics (ER/PR/HER2 status, grade, presence of lymph node metastases, stage), demographics (age, race), clinical factors (menopausal status), treatment regimens (chemotherapy use and type, endocrine therapy use and type, radiation use), family history of breast or ovarian cancer, and any evidence of recurrence. Anthropometric variables were measured in our outpatient clinic by trained staff. If weights were not available within 2 months of the desired time point, data were recorded as missing.

DNA isolation
-------------

Blood samples were collected for genotyping of polymorphisms in *FTO*, *ADIPOQ*, and *ADIPOR1*. DNA from whole blood lymphocytes was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) and was stored at −20 °C until use for genotyping.

Selection of SNPs
-----------------

*ADIPOQ* has \>10 single-nucleotide polymorphisms (SNPs; [@bib27]; [@bib73]) and two linkage disequilibrium (LD) blocks with a block boundary between −2049 and −450 ([@bib58]). We selected to genotype haplotype tagging SNPs rs266729 (5′ flanking region), rs822396 (intron 1), and rs822395 (intron 1) to tag block 1 and rs150129 (exon 2) and rs2241766 (intron 2) to tag block 2 as these are the five most common SNPs and have been studied more extensively by others as to their functionality and relation to diseases such as diabetes mellitus ([@bib27]; [@bib58]; [@bib16]; [@bib31]). *ADIPOR1* has \>28 SNPs and two LD blocks ([@bib67]). One block extends from the 5′ flanking region to intron 4 and the other is located at the 3′ end of the gene. Based on this, we selected five common haplotype tagging SNPs for genotyping. For block 1, we selected the following tagging SNPs: rss2232853 (5′ flanking region), rs12733285 (intron 1), and rs134238 (intron 4). For block 2, we selected rs7539542 (exon 8) and rs10920531 (3′ flanking region). These SNPs were selected because they correspond to both LD blocks. All selected SNPs have been previously studied in relation to breast cancer risk by our group ([@bib43]).

We selected four SNPs in *FTO* to evaluate. These SNPs were selected based on previous data from GWAS ([@bib34]; [@bib23]; [@bib69]) as well as our own published data on their association with breast cancer risk ([@bib41]). More specifically, rs9939609 has been previously identified to be significantly associated with obesity and diabetes mellitus ([@bib23]; [@bib71]; [@bib69]; [@bib82]). Furthermore, other SNPs in the same LD block (rs1121980, rs9939973, rs7193144, rs9940128, and rs8050136) were found to be associated with obesity ([@bib34]). The SNPs we selected to evaluate are all in intron 1 of *FTO* and represent LD block 6 (rs7206790 and rs8047395) and LD block 7 (rs9939609 and rs1477196).

Genotyping
----------

Genotyping for the 14 SNPs was performed by Taqman SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Forest City, CA, USA). Results were ascertained by using the SDS software version 2.3 (Applied Biosystems). All results were automatically called (i.e., the device displays the genotypes automatically with a 95% certainty). A total of 5% of samples were genotyped in duplicate and showed 100% concordance. A total of 31 of the 459 patients had missing blood samples so these patients were not included in the genetic analyses.

Statistical analysis
--------------------

Data were first analysed descriptively to determine whether or not any missing values and outliers exist. Hardy--Weinberg equilibrium was checked for each SNP. Generalised linear models were implemented to explore the relationship between the weight change and SNPs or covariates, both in a single-SNP or single-covariate analysis and in a multiple-SNP analysis.

In the multiple-SNP analysis, we considered an epistatic model in which the main effects of SNPs as well as their possible epistatic interactions were fitted in the model. The purpose of including epistatic interactions in a model is to understand how the effect of a SNP depends on the presence or absence of another SNP, and to aid discovery of some SNPs that affect the weight change mainly through their epistatic effects. For both the single-SNP and multiple-SNP analyses, we studied the influence of SNPs on the weight change adjusted for the covariates that are statistically significant in the single-covariate analysis.

To facilitate the analysis of epistatic interactions in a model, we used the Cockerham genetic model to encode the main effects of SNPs. We denoted the common homozygote (i.e., the homozygote of a SNP with a higher frequency), heterozygote, and rare homozygote for each SNP by *c*, *h*, and *r*, respectively. The Cockerham model defines two main effects for each SNP, an additive contrast as −1, 0, and 1 for *c*, *h*, and *r*, and a dominance contrast as −0.5 for *c* and *r* and 0.5 for *h*, respectively ([@bib9]; [@bib45]). The additive effect represents the genotypic effect (*r--c*)/2, and the dominance effect measures *h--*(*c*+*r*)/2 in the probability of being cases. A positive additive effect indicates that the rare homozygote increases the possibility of weight change compared with the common homozygote, and a positive dominance effect means that the heterozygote increases the possibility of weight change compared with the mean of two homozygotes. Accordingly, the epistatic predictors are constructed by multiplying two corresponding main effects of SNPs, introducing four epistatic interactions for a pair of SNPs, that is, additive--additive, additive--dominance, dominance--additive, and dominance--dominance interactions.

For the covariates, we encoded binary exposure as 0 and 1, and standardised other exposures to have a mean of 0 and a s.d. of 0.5. This scaling scheme puts continuous variables on the same scale as symmetric binary variables.

We used the Bayesian hierarchical normal linear model ([@bib50]; [@bib2]; [@bib49]; [@bib33]) because the classical normal linear models have problems such as nonidentifiability of parameters, computational inefficiency, and limited statistical power for detecting causal variants when there are a large number of genetic factors and interactions, even if highly correlated ([@bib50]; [@bib2]; [@bib49]; [@bib33]). This Bayesian model can overcome these problems mainly by placing some appropriate prior distributions on parameters. Specifically, we assume independent Student\'s *t* priors, , on parameters in the model. We are motivated to use the *t* distribution because it can produce robust inference, shrinkage estimation, and easy computation ([@bib19]; [@bib80]; [@bib79]). The *t* distribution can be expressed as a mixture of normal distributions with mean 0 and variance distributed as scaled inverse-

where *J* is the total number of parameters and is the *j*th parameter in the model, and the hyperparameters and can be predetermined reasonably. For the main effects, we set . For epistatic interactions, we set , where *k*~G~ and *k*~GG~ are the total numbers of main and epistatic interaction effects of SNPs, respectively. These priors apply more stringent restrictions on interactions. We fitted our hierarchical normal linear models by incorporating an expectation-maximisation algorithm into the usual iteratively weighted least squares for classical normal linear models.

To explore the factors that influence the higher and lower BMI changes, we conducted a quartile analysis. To this end, we first divided BMI change into four equal groups and select a sub-data set in which the patients have BMI change in the lower (⩽25%) and upper (⩾75%) quartiles. We then encoded BMI change in the lower quartile as 0 and the upper quartile as 1. Given this data, we re-run the statistical analyses described above and used odds ratio (OR) to measure the effect sizes of SNPs and covariates of interest on the BMI change.

To make model selection and interpretation of results more proper, we compared and contrasted the deviance and the Akaike information criterion (AIC) between different models. The deviance, defined as −2 times the log-likelihood, is a measure of goodness of fit; smaller deviance means better fit to data. AIC, defined as deviance plus 2 times the number of predictors, measures the predictive power; a model is estimated to reduce out-of-sample prediction error if AIC decreases.

To assess the predictive accuracy of our models for weight gain, we performed receiver operating characteristics (ROCs) analysis, including estimation of true-positive rate (also known as sensitivity) and false-positive rate (i.e., 1 -- specificity), estimation of an ROC curve, and computing the area under the ROC curve (AUC). We conducted the analysis based on the two models: main effect model and epistatic model.

Results
=======

Baseline characteristics
------------------------

Of the 562 patients initially enrolled in the study, 459 had adequate data to be included in our analysis. Of the 103 patients who were not included in the analysis, only 5 were lost to follow-up. Twenty-seven of the patients not included met exclusion criteria that were missed on initial recruitment: 15 had metastatic cancer, 5 had ductal carcinoma *in situ*, 2 had lobular carcinoma *in situ*, 3 were pregnant, and 2 had a concurrent malignancy. The remaining patients had missing weight data either at baseline or on follow-up that precluded data analysis.

[Table 1](#tbl1){ref-type="table"} highlights the baseline patient characteristics and [Table 2](#tbl2){ref-type="table"} the treatment characteristics of the 459 patients included in our analyses. The average patient age was 51.3 (s.d. 10.9) years old with the majority being Caucasian (74.5%) and the most common minority population being African American. The mean baseline BMI was 27.5 kg m^--2^, classified in the overweight category, and mean baseline weight 74.2 kg. About 70% of the patients received chemotherapy and radiation therapy, with the most common chemotherapy regimen being doxorubicin at 60 mg m^--2^ and cyclophosphamide at 600 mg m^--2^ i.v. every 2 weeks for four cycles followed by paclitaxel at 175 mg m^--2^ every 2 weeks for four cycles (ddACT), and 78% received endocrine therapy with tamoxifen being the most commonly used agent. [Supplementary Table 1](#sup1){ref-type="supplementary-material"} shows the distribution of SNP alleles for the 4 *FTO* and 10 adiponectin pathway polymorphisms being evaluated in this study along with allele frequencies. In all, \<1% of the SNP data are listed as undetermined, indicating that the analyser was unable to determine the specific allele; each of these samples was run twice for confirmation.

Weight gain
-----------

As seen in [Table 3](#tbl3){ref-type="table"}, 33% of patients at 6 months and 56% at 18 months had a BMI increase of \>0.5 kg m^--2^ from baseline. Average weight gain among these patients was 3.5 kg (s.d. 2.36 kg) at 6 month and 5.1 kg (s.d. 3.76 kg) at 18-month follow-up, with corresponding BMI increases from 1.3 kg m^--2^ (s.d. 0.84 kg m^--2^) to 1.9 kg m^--2^ (s.d. 1.42 kg m^--2^). To better evaluate clinically significant weight gain, we looked at \>5% increase in baseline BMI and found that 13% of patients at 6 months and 36% at 18 months had gained this amount of weight. The maximum BMI increase was 9 kg m^--2^ at 18 months (38% increase in BMI), with maximum weight increase of 23.4 kg.

Univariate analysis of clinical variables
-----------------------------------------

[Supplementary Table 2](#sup1){ref-type="supplementary-material"} shows the significant clinical variables in the univariate analysis at each time point of 6, 12, and 18 months from breast cancer diagnosis. Results for our analyses are expressed in effect sizes, with each value quantifying the relative change in BMI with variable of interest, for example −0.106 for BMI at diagnosis indicating that each additional increase in BMI by 1 kg m^--2^ at diagnosis is associated with 0.106 kg m^--2^ less increase in BMI by 6 months. Quartile analysis data is also included and expressed as ORs comparing likelihood of being in the upper quartile of weight gain compared with lower quartile with variable of interest. Results show that BMI at diagnosis and age were both negatively correlated with weight gain with younger and lower weight patients being at higher risk of weight gain. Weight gain was also associated with lower stage, ER/PR-positive markers, use of endocrine therapy, and absence of chemotherapy. Among the chemotherapy regimens, docetaxel 75 mg m^--2^ and cyclophosphamide 600 mg m^--2^ (TC) i.v. every 3 weeks for four cycles was associated with less weight gain. There was some support for weight gain with premenopausal status at diagnosis (weight gain associated with premenopausal\>postmenopausal\>perimenopausal), menopausal change from premenopausal to peri/postmenopausal, absence of lymph node metastases, lower tumour grade, tamoxifen use, and white race though results were not significant across all time points. It should be noted that menopause classification was obtained from what was labelled in chart review and not based on serum markers. Menopausal status was more clearly specified in the diagnosis history and physical notes but at 1 year was only mentioned clearly in some patients\' charts and in other cases postmenopausal status was inferred from descriptions of no menses for \>1 year. Given the lack of thorough charting in follow-up notes, approximately 10% of 1-year data on menopausal status are missing, as can be seen in [Table 1](#tbl1){ref-type="table"}. No statistically significant differences in weight gain were seen at any time points for radiation therapy, family history, HER2 status, or menopausal status at 1 year.

Single SNP analysis
-------------------

Single SNP analyses were conducted using a generalised linear model with effect sizes and quartile analyses with ORs, adjusting for clinical covariates. Results are as shown in [Table 4](#tbl4){ref-type="table"}. One *FTO* SNP (rs7206790) and six adiponectin pathway SNPs (rs1342387, rs822396, rs2232853, rs1501299, rs7539542, and rs10920531) were found through additive or dominance effects to be associated with weight gain for at least one time point, with the adiponectin rs822396 SNP through additive effects being the only one to show significance at two time points.

Multivariate analysis
---------------------

We used the Bayesian hierarchical generalised linear model for our multivariate analysis. This was performed using both epistatic and non-epistatic models as well as models including the *FTO* SNPs alone, the adiponectin pathway SNPs alone, and a combination of both sets of SNPs. The epistatic model using both sets of SNPs showed the best fit with smallest deviance and so was chosen to interpret our results as shown in [Table 5](#tbl5){ref-type="table"}. Also included are the results of multivariate quartile analysis. Paying particular attention to the SNPs that are significant at the 12-month or final 18-month points either individually or part of an interaction, rs822396, rs266729, rs1342387, and rs7539542 are notable. For the clinical variables, age and BMI were again significant across multiple time points (though age lost significance at 18 months) with younger and lower BMI women being at higher risk for weight gain, consistent with our univariate analysis. Oestrogen receptor status positivity, absence of chemotherapy, and lower stage were also associated with increased weight gain, although stage was only significant at the 6-month time point.

Predictive models
-----------------

We created several clinical, genetic, and combination models using the above data to predict the post-diagnosis weight gain in our patients. As described in the Materials and Methods section, discriminatory power of our predictive models was assessed by performing ROC analysis ([Figure 1](#fig1){ref-type="fig"}). The ROC curves show the estimated true-positive and the false-positive rates for different classification thresholds between 0 and 1. The AUC represents the probability that given two random individuals, one who will develop the disease and the other who will not, the predictive model will assign the former as a positive test and the latter as a negative test. A perfect predictive model would have an AUC of 1. It has been suggested that an AUC\>0.5 has some discriminatory ability and for screening high-risk individuals an AUC\>0.75 should be used ([@bib39]).

A traditional clinical model was generated with the significant variables on univariate analysis and yielded AUCs of 0.51, 0.50, and 0.47 for 6, 12, and 18-month weight gains, respectively. For the genetic SNP models, analyses were conducted on both main effect and epistatic models for *FTO* SNPs alone, adiponectin pathway SNPs alone, and the combination of both at each time point. We performed the analyses first by focusing on only the significant SNPs seen in the above multivariate analysis and then by including all the SNPs. We found that an epistatic model incorporating all 14 SNPs had highest AUCs with values of 0.84, 0.81, and 0.79 for 6, 12, and 18-month weight gains, respectively. In comparison, the epistatic model incorporating only significant SNPs had AUCs of 0.57, 0.59, and 0.24 and the main effects model with all 14 SNPs had AUCs of 0.6, 0.6, and 0.59. Incorporating both *FTO* and adiponectin pathway SNPs yielded higher AUC values than including only one of these groups. Using our most predictive model of all 14 SNPs and their epistatic interactions, we analysed several combinations with clinical variables and found that incorporating all significant clinical variables decreased the AUCs to values of 0.55, 0.48, and 0.52. In contrast, addition of only the baseline age and BMI yielded our most powerful model, as illustrated in [Figure 1](#fig1){ref-type="fig"}, with AUC values of 0.90, 0.88, and 0.85, for 6, 12, and 18-month weight gains, respectively.

Discussion
==========

Using a retrospective cohort analysis of 459 breast cancer patients, we were able to construct a primarily SNP-based predictive model with high discriminatory power for post-diagnosis weight gain. We tested multiple predictive models, including a traditional clinical model, genetic model using *FTO* and adiponectin pathway SNPs, and combination models, and we found that a model incorporating all 14 SNPs (from *FTO*, *ADIPOQ*, and *ADIPOR1*) studied in addition to their epistatic interactions and baseline age and BMI was most predictive of weight gain with AUC as high as 0.90 for 6-month weight gain and 0.85 for 18-month weight gain.

In creating these models, we initially evaluated for specific polymorphisms±epistatic interactions with significant associations to weight gain as highlighted in [Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}. Notably, rs822396 (*ADIPOQ*) was statistically significant across our different genetic analyses presented -- linear univariate analysis, multivariate analysis, and quartile analyses. We previously showed this polymorphism contributes to risk of prostate and colon cancer and other groups have shown increased risk of type 2 diabetes and ischaemic stroke ([@bib30]; [@bib44], [@bib42]; [@bib59]), but this is the first published correlation to post-diagnosis weight gain in breast cancer patients. The other SNPs listed in the multivariate analysis were less consistently significant across different analyses and time points. Aside from rs822396, the other significant genetic findings at 12- or 18-month time points were interactions among rs266729 (*ADIPOQ*), rs1342387 (*ADIPOR1*), and rs7539542 (*ADIPOR1*). In addition to also having associations with risk of prostate and colon cancer, type 2 diabetes, and ischaemic stroke, these SNPs have been linked to coronary artery disease, hypertension, and efficacy of weight loss products such as sibutramine ([@bib30]; [@bib65]; [@bib44]; [@bib36]; [@bib26]; [@bib29]; [@bib53]; [@bib42]; [@bib57]; [@bib59]; [@bib78]; [@bib81]). Receiver operating characteristic analysis of an epistatic model of significant SNPs on multivariate analysis only showed AUC of 0.24 for 18-month weight gain. When the models were expanded to include all 14 SNPs, this value increased to 0.79, highlighting the loss of discriminatory power with limiting analysis to only selected SNPs; of note, analysis with only the 10 adiponectin pathway SNPs or the 4 *FTO* SNPs yielded lower AUC values as well.

To create a clinical predictive model and isolate variables for a combined genetic and clinical model, we assessed various demographic and clinical variables. We found that younger patients and those with lower BMI at diagnosis are more likely to gain weight, which is consistent with other studies ([@bib61]; [@bib38]; [@bib46]; [@bib3]; [@bib62]; [@bib24]). Although there was a general trend that Hispanics gained more weight than whites who gained more weight than Asians and African Americans, this was not shown to be significant in our analyses.

In terms of treatment factors, chemotherapy was actually associated with decreased weight gain in multivariate analysis at 6- and 12-month time points and lost significance at the final 18-month time point. Historically, chemotherapy has been thought to contribute to weight gain as seen in many prior studies ([@bib61]; [@bib46]; [@bib3]; [@bib62]; [@bib32]; [@bib24]). Several studies have contradicted this and proposed that the shorter duration regimens that are now used such as TC regimens do not cause this weight gain ([@bib13]; [@bib48]; [@bib18]; [@bib37]). As seen in [Table 1](#tbl1){ref-type="table"}, the majority of our patients received adriamycin/cyclophosphamide, TC, or ddACT regimens as opposed to the longer FEC and CMF regimens, which are included in the 'other\' category.

Effect of menopausal status has been conflicting in the literature with the majority of reports showing increased weight gain with premenopausal status ([@bib4]; [@bib61]; [@bib3]; [@bib5]; [@bib32]) or absence of effect ([@bib1]; [@bib10]; [@bib51]; [@bib25]) and the minority showing weight gain with postmenopausal status ([@bib38]). Our study showed premenopausal status at diagnosis was associated with weight gain in univariate analysis but after adjusting for other significant clinical variables as well as SNPs, found no significant difference. Consistent with some other studies, we showed that the subset of patients who underwent transition from premenopausal status at diagnosis to postmenopausal at 1 year gained weight ([@bib22]; [@bib5]) although this too lost significance in multivariate analysis. It is important to mention that the menopausal status was gathered from chart review and was not based on objective evaluation. This chart review process likely decreased the accuracy of menopausal status categorisation, in particular decreasing the frequency of patients assigned as 'postmenopausal\' at 1 year or 'perimenopausal\' at either time point. It is possible that this limited our power to find a relationship between premenopausal to postmenopausal transition at 1 year and post-diagnosis weight gain.

With respect to tumour characteristics, our study interestingly found that oestrogen receptor positivity was found to be associated with weight gain at each time point in both the univariate and multivariate analyses. This association has only been weakly demonstrated in the literature ([@bib22]) with most studies finding no correlation ([@bib4]; [@bib25]; [@bib24]). Further studies will need to continue exploring hormone receptor status as a causative factor. We did not find strong consistent correlations for other tumour characteristics. Lower stage tumours were associated with weight gain at 6 months but lost significance by 12 months and lymph node metastases were not found to be significant at any time point. Similarly, low-grade tumours were only significant at 18 months by quartile analysis, which is a less robust statistical analysis than the linear model using effect sizes. More of the literature supports weight gain with higher stage tumours ([@bib14]; [@bib22]; [@bib38]; [@bib24]) but there is also contradictory literature ([@bib61]; [@bib46]).

We created a predictive clinical model incorporating significant findings and found an AUC of only 0.47 at 18-month time point, indicating the generally low discriminatory ability of the clinical variables and perhaps explaining the conflicting findings in the literature for the majority of these variables. We also created combination models with the 14 SNPs and their epistatic interactions as the base and found that adding all the significant covariates decreased the AUC from 0.79 at 18 months to 0.52. The model, however, was enhanced by adding only baseline age and BMI with resulting AUC of 0.85. This combination model of 4 *FTO* SNPs+10 adiponectin pathway SNPs+epistatic interactions+baseline age+baseline BMI was therefore our optimal model with highest predictive power.

Our study has several strengths and limitations. One limitation of this retrospective cohort study is that the weights were obtained by chart review. However, although weight was not measured on a standardised scale at each visit, it was still measured during clinic visits as opposed to via patient self-reporting, so it is unclear how much this affected the results if at all. We excluded weight data that were not within 2 months of our desired time points, thereby maximising accuracy of our measurements. We are currently conducting a prospective study of 300 breast cancer patients who will be weighed at 6-month intervals in a controlled setting to better address this limitation. As mentioned above, menopausal status, especially at 1 year, may also have been inaccurate because of the retrospective nature of this study. Another limitation is that the study design did not have a control group of matched non-breast cancer patients to compare weight gain trends and the predictive role of the polymorphisms and clinical variables studied. Although this data would have been interesting, it is not clinically relevant as post-breast cancer diagnosis weight gain, irrespective of what proportion is secondary to the breast cancer diagnosis and subsequent treatments, is associated with poor outcomes and needs to be minimised. The median age of our patients is lower than that of the United States ([@bib20]). However, previous published work from our group includes patients of similar demographics (Kaklamani *et al*, 2008a; Kaklamani *et al*, 2011a) depicting the patient population seen in our centre. We do not believe that this impacts on our results. The strengths of our study are the large number of patients included in the cohort and the combination analysis of clinical and genetic characteristics.

This is the first study to evaluate the effects of genetic polymorphisms as well as their gene × environment interactions on post-diagnosis weight gain in breast cancer patients. Our final model shows high discriminatory power with AUCs of 0.90, 0.88, and 0.85 for weight gain at 6, 12, and 18 months post-diagnosis, respectively. We are currently conducting a prospective study of 300 newly diagnosed breast cancer patients to validate this predictive model. This risk assessment tool could allow us to identify patients at highest risk for weight gain and target them for weight loss interventions starting at the time of diagnosis. Numerous interventions have been published for this patient population, including diet ([@bib12]; [@bib56]; [@bib40]; [@bib8]; [@bib35]), exercise ([@bib63]; [@bib64]), and multidisciplinary ([@bib21]; [@bib6]; [@bib28]) approaches with mixed results and limited long-term data on sustained weight loss. In addition, wide spread implementation of weight loss intervention is less feasible than in a limited population. With a targeted population, the interventions can be more effective, future clinical trials more efficient, and resources more intelligently appropriated. We hope this strategic approach will more effectively prevent the post-diagnosis weight gain seen in breast cancer patients and thereby decrease the associated morbidity and mortality.

This study was supported by grants funded by Lynn Sage Foundation (VGK), Dolores Knes Fund (VGK), National Institute of Diabetes and Digestive and Kidney Diseases grants 58785, 79929 and 81913 (CSM), Award Number 1I01CX000422-01A1 from the Clinical Science Research and Development Service of the VA Office of Research and Development (CSM).

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

![**ROC curves at 6, 12, and 18 months.** Solid line indicates ROC curve for the significant clinical variable model (AUC=0.51 at 6 months, 0.50 at 12 months, and 0.47 at 18 months), dashed line indicates ROC curve for the 14 SNPs model (AUC=0.60 at 6 months, 0.59 at 12 months, and 0.58 at 18 months), and dotted line indicates ROC curve for the 14 SNPs+epistatic interactions+age+BMI at diagnosis model (AUC=0.90 at 6 months, 0.88 at 12 months, and 0.85 at 18 months). The grey line represents AUC of 0.5.](bjc2013441f1){#fig1}

###### Baseline characteristics of 459 patients

                                   **Mean (range)**
  ------------------------------ --------------------
  Age (years)                       51.3 (26--84)
  BMI at diagnosis (kg m^--2^)    27.5 (14.9--51.9)
  Weight at diagnosis (kg)        74.2 (36.4--144.1)
                                       *N* (%)
  **Race**                       
  Caucasian                           342 (74.5)
  African American                    68 (14.8)
  Asian                                22 (4.8)
  Hispanic                             20 (4.4)
  Unknown                              7 (1.5)
  **Stage at diagnosis**         
  I                                   158 (34.4)
  II                                  194 (42.3)
  III                                 106 (23.1)
  Unknown                             1 (\<0.1)
  **Lymph node metastases**      
  \+                                  232 (50.5)
  −                                   217 (47.3)
  Unknown                              10 (2.2)
  **Tumour grade**               
  1                                   84 (18.3)
  2                                   196 (42.7)
  3                                   163 (35.5)
  Unknown                              16 (3.5)
  **ER status**                  
  \+                                  367 (80.0)
  −                                   92 (20.0)
  **PR status**                  
  \+                                  323 (70.4)
  −                                   132 (28.8)
  Unknown                              4 (0.9)
  **Her2 status**                
  \+                                  78 (17.0)
  −                                   366 (79.7)
  Unknown                              14 (3.3)
  **Menopause at diagnosis**     
  Premenopausal                       222 (48.4)
  Perimenopausal                       22 (4.8)
  Postmenopausal                      204 (44.4)
  Unknown                              11 (2.4)
  **Menopause at 1 year**        
  Premenopausal                       112 (24.4)
  Perimenopausal                       31 (6.8)
  Postmenopausal                      272 (59.3)
  Unknown                              44 (9.6)
  **Family history**             
  \+                                  194 (42.3)
  −                                   254 (55.3)
  Unknown                              11 (2.4)

Abbreviation: BMI=body mass index; ; ER = estrogen receptor; PR = progesterone receptor.

###### Baseline treatment characteristics

                                                                   ***N*** **(%)**
  ---------------------------------------------------------------- -----------------
  **Radiation**                                                    
  \+                                                               322 (70.2)
  −                                                                131 (28.5)
  Unknown                                                          6 (1.3)
  **Chemotherapy**                                                 
  \+                                                               325 (70.8)
  −                                                                134 (29.2)
  **Type of chemotherapy**                                         
  AC × 4                                                           66 (20.3)
  TC × 4                                                           23 (7.1)
  Anthracycline + taxane chemotherapy[a](#t2-fn2){ref-type="fn"}   194 (59.7)
  Other[b](#t2-fn3){ref-type="fn"}                                 42 (12.9)
  **Endocrine therapy**                                            
  \+                                                               359 (78.2)
  −                                                                99 (21.6)
  Unknown                                                          1 (0.2)
  **Type of endocrine therapy**                                    
  Tamoxifen × 5 years                                              150 (41.8)
  Aromatase inhibitor × 5 years                                    134 (37.3)
  Tamoxifen × 5 years followed by aromatase inhibitor              72 (20.1)
  Unknown or other                                                 9 (2.5)

Abbreviations: AC=adriamycin/cyclophosphamide; TC=taxotere/cyclophosphamide.

Includes AC, then taxol (T) × 8, AC then T weekly, dose dense ACT, taxotere/AC, and AC then T + herceptin.

Includes lapatinib, lapatinib/abraxane, lapatinib/abraxane/herceptin, cyclophosphamide/doxorubicin/5-fluorouracil, 5-fluorouracil/epirubicin/cyclophosphamide, taxotere/navelbine, taxol alone, carboplatin-taxotere, herceptin.

###### Weight changes in patient population

                                                                   **6 Months**              **12 Months**             **18 Months**
  ---------------------------------------------------------- ------------------------- ------------------------- -------------------------
  Average BMI (weight) change                                 0.07 kg m^--2^ (0.3 kg)   0.32 kg m^--2^ (1.0 kg)   0.56 kg m^--2^ (1.9 kg)
  \% Of patients with \>0.5 kg m^--2^ ↑ BMI                            33.0%                     49.0%                     56.0%
  Average BMI (weight) increase[a](#t3-fn2){ref-type="fn"}    1.3 kg m^--2^ (3.5 kg)    1.6 kg m^--2^ (4.4 kg)    1.9 kg m^--2^ (5.1 kg)
  \% Of patients with \> 5% ↑ BMI                                      13.0%                     27.0%                     36.0%
  Average BMI (weight) increase[b](#t3-fn3){ref-type="fn"}    2.0 kg m^--2^ (5.5 kg)    2.3 kg m^--2^ (6.1 kg)    2.5 kg m^--2^ (6.7 kg)
  Maximum BMI % ↑                                                      18.0%                     31.0%                     38.0%
  Maximum BMI (weight) ↑                                      5.0 kg m^--2^ (15.1 kg)   6.4 kg m^--2^ (16.5 kg)   9.0 kg m^--2^ (23.5 kg)

Abbreviation: BMI=body mass index.

Among patients with \>0.5 kg m^--2^ ↑ BMI.

Among patients with \>5% ↑ BMI.

###### Significant SNPs in single SNP analyses[a](#t4-fn3){ref-type="fn"} [,b](#t4-fn4){ref-type="fn"}

                          **6 Months (effect size**[c](#t4-fn5){ref-type="fn"})   **12 Months (effect size)**   **18 Months (effect size)**
  ----------------------- ------------------------------------------------------- ----------------------------- -----------------------------
  *ADIPOQ* rs822396a                                                              0.186\*\*                     0.208\*\*
  *ADIPOR1* rs2232853d                                                            0.122\*                        
  *ADIPOQ* rs1501299a                                                             −0.108\*                       
  *FTO* rs7206790d                                                                                              −0.112\*
  *ADIPOR1* rs7539542a                                                                                          −0.114\*\*
  *ADIPOR1* rs7539542d                                                                                          0.117\*
  *ADIPOR1* rs10920531a                                                                                         −0.077\*

Abbreviations: BMI=body mass index; SNP=single-nucleotide polymorphism.

\**P*\<0.05, \*\**P*\<0.01.

Adjusted for significant clinical variables in descriptive analysis: at 6 months for BMI at diagnosis, age, race, stage, lymph node metastases, estrogen receptor status, progesterone receptor status, chemotherapy, and hormone therapy; at 1 year for BMI at diagnosis, age, stage, estrogen receptor status, menopause status at diagnosis, chemotherapy, and hormone therapy; at 18 months for BMI at diagnosis, race, estrogen receptor status, menopause status at diagnosis, menopause transition from pre to postmenopausal at 1 year, and hormone therapy. Quartile analyses were adjusted for all clinical variables at each time point.

No significant findings on quartile analysis.

Effect size defined as difference in BMI gain with presence of the variable of interest. Positive values denote relative increase in BMI gain by that quantity. Negative values denote relative decrease in BMI gain by that quantity.

###### Multivariate analysis using Bayesian hierarchical generalised linear model

                             **6 Months (effect size**[a](#t5-fn3){ref-type="fn"})   **12 Months (effect size)**   **18 Months (effect size)**   **Quartile analysis**[b](#t5-fn4){ref-type="fn"} **at 6 months (OR)**   **Quartile analysis at 12 months (OR)**   **Quartile analysis at 18 months (OR)**
  -------------------------- ------------------------------------------------------- ----------------------------- ----------------------------- ----------------------------------------------------------------------- ----------------------------------------- -----------------------------------------
  Age                        −0.144\*                                                −0.110\*\*                                                                                                                                                                     
  BMI at diagnosis                                                                   −0.083\*                      −0.140\*\*                                                                                                                                       
  Stages II *vs* III         0.117\*                                                                                                                                                                                                                                
  Chemotherapy               −0.179\*\*                                              −0.097\*                                                                                                                                                                       
  ER positive                0.223\*                                                 0.134\*\*                     0.224\*\*                                                                                                                                        
  Grades 2 *vs* 3                                                                                                                                                                                                                                                  0.158\*
  rs7206790a                 −0.082\*                                                                                                                                                                                                                               
  rs8047395a                 0.078\*                                                                                                                                                                                                                                
  rs1501299a                 −0.112\*\*                                                                                                                                                                                                                             
  rs10920531a × rs822396a    −0.100\*\*                                                                                                                                                                                                                             
  rs12733285d × rs1501299a   −0.228\*\*                                                                                                                                                                                                                             
  rs12733285d × rs9939609d   −0.314\*\*                                                                                                                                                                                                                             
  rs1342387d                                                                         −0.104\*\*                                                                                                                                                                     
  rs266729d                                                                          −0.994\*\*                                                                                                                                                                     
  rs1342387d × rs266729d                                                             −0.209\*\*                                                                                                                                                                     
  rs266729d × rs7539542d                                                                                           0.466\*\*                                                                                                                                        
  rs822396a                                                                                                                                                                                                                                                        0.236\*

Abbreviations: BMI=body mass index; ER = estrogen receptor; OR=odds ratio.

\**P*\<0.05, \*\**P*\<0.01.

Effect size defined as difference in BMI gain with presence of the variable of interest. Positive values denote relative increase in BMI gain by that quantity. Negative values denote relative decrease in BMI gain by that quantity.

Quartile cutoffs were ⩽−0.54 kg m^--2^ and ⩾0.73 kg m^--2^ at 6 months, ⩽−0.40 kg m^--2^ and ⩾1.20 kg m^--2^ at 12 months, and ⩽−0.22 kg m^--2^ and ⩾1.64 kg m^--2^ at 18 months for lower (⩽25%) and higher quartiles (⩾75%), respectively.
